COVID-19
Shares in the company shot up 212.6% following the news it had isolated the potentially variant-neutralizing antibodies.
An open letter from a group of academics is urging the Biden administration to implement updates to guidance and standards that will better protect high-risk workers from the novel coronavirus that causes coronavirus disease 2019 (COVID-19).
With distribution of COVID-19 vaccines being slow, public health officials and researchers are trying to develop schemes and rationales for delaying the dosing of the second shots.
Several mutations of the SARS-CoV-2 virus that causes COVID-19, which are being called variants, are increasingly being found around the world.
Currently, research is still ongoing with regards to the link between COVID and POTS. However, this increasing number of cases and the unfamiliarity of COVID’s long-lasting effects leave a lot more for the researchers to unmask.
COVID-19 reinfections are occurring but, so far, scientists don’t have all the details.
With the COVID-19 vaccine rollout underway and a renewed sense of hope stemming from an aggressive vaccine dispersal plan, a common question has begun to emerge.
In an editorial letter in The New England Journal of Medicine, Jeff Shuren, M.D., the FDA’s device center director, and the agency’s in vitro diagnostics chief Timothy Stenzel, M.D., Ph.D., wrote that the agency planned to revisit their policy on antibody testing after it had authorized several serology tests.
In 2020, Vir and GlaxoSmithKline partnered to develop strategies against COVID-19. The two companies have expanded that collaboration to include work into new treatments for influenza and other respiratory viruses.
As COVID-19 vaccine rollouts intensify across the country, employers across all industries are trying to decide whether they should implement a mandatory vaccine policy before they let employees back into the office.
PRESS RELEASES